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Radiofrequency ablation (RFA) provides an effective technique for minimally invasive tissue destruction. An alternating current
delivered via a needle electrode causes localised ionic agitation and frictional heating of the tissue around the needle. Image-guided,
percutaneous ablation techniques have been developed in most parts of the body, but the most widely accepted applications are for
the treatment of hepatocellular carcinoma (HCC) in early cirrhosis, limited but inoperable colorectal liver metastases, inoperable
renal cell carcinoma and inoperable primary or secondary lung tumours. The procedures are well tolerated and the complication
rates low. Patients with coexistent morbidity who are not suitable for surgery are often able to undergo RFA. Most treatments in the
lung, kidney and for HCC are performed under conscious sedation with an overnight hospital stay or as a day-case. Larger more
complicated ablations, for example, in hepatic metastases may require general anaesthesia. Limitations of RFA include the volume of
tissue that can be ablated in a timely fashion, that is, most centres will treat 3–5 tumours up to 4–5cms in diameter. Early series
reporting technical success and complications are available for lung and renal ablation. Liver ablation is better established and 5-year
survival figures are available from several centres. In patients with limited but inoperable colorectal metastases, the 5-year survival
ranges from 26 to 30% and for HCC it is just under 50%. In summary, RFA provides the opportunity for localised tissue destruction of
limited volumes of tumour; it can be offered to nonsurgical candidates and used in conjunction with systemic therapy.
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Image guided ablation dates to 1989 when the first US guided
interstitial laser treatments were performed in liver metastases and
the first percutaneous ethanol injections were reported for the
treatment of small hepatocellular carcinoma (HCC). Rapid
technological developments have resulted in the development of
a number of ablative techniques, higher power generators and a
range of different electrode designs. Current designs permit
ablation of much larger volumes of tissue than was originally
possible. Radiofrequency ablation (RFA) has been used in a wide
range of locations and applications including adrenal metastases,
primary colorectal cancer recurrence and malignant pelvic or para-
aortic lymphadenopathy (Lees and Gillams, 2005), but in this
article we will consider the main areas where RFA has proven
effective or is likely to do so.
TECHNICAL FEATURES
Radiofrequency ablation uses needle electrodes to deliver an
alternating current that generates ionic agitation, localised
frictional tissue heating and cell death. A range of electrode
designs is available ranging in caliber from 14 to 1 7G. Most are
designed to be inserted percutaneously using image guidance.
Various design features have been put forward (water cooling,
saline perfusion, monopolar or bipolar, coil or expandable
designs), all aimed at increasing the volume of confluent necrosis
that can be achieved per unit time. Ultrasound (US) is the
preferred technique for electrode placement but where US is not
possible, for example, in lung ablation or in US occult liver
tumours, then CT or MR are used. Assessment of the efficacy of
ablation is achieved using contrast-enhanced CT or MR. Absent
enhancement denotes the area of necrosis. Thermal techniques
result in coagulation necrosis and an ‘instantaneous thermal
fixation’ effect. Tissue architecture is preserved, routine histolo-
gical stains are misleading and enzymatic assays are required to
establish tissue nonviability (Ni et al, 2005).
LIVER METASTASES
Colorectal
This patient population represents one of the most common
indications for RFA in the UK. Liver resection is currently
considered the first line of treatment for those with surgical
disease, but there are many patients who are not suitable for
resection either because of comorbidity, tumour location or
inadequate hepatic reserve (most commonly in patients who have
undergone a previous resection). These patients may well benefit
from RFA to the liver either in isolation or in conjunction with
systemic chemotherapy. As liver metastases usually arise in an
otherwise normal liver, the extent of disease that can be safely
treated is greater than for patients with HCC arising on a
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www.bjcancer.combackground of cirrhosis. Most centres will accept patients with as
many as five tumours, maximum diameter 5cm. We have
published our survival results in 167 patients with colorectal
metastases treated with RFA but have now treated over 215
patients (Gillams and Lees, 2004). A total of 96 patients conformed
to the above criteria and their survival was a median, 1, 3 and 5
years from the diagnosis of liver metastases of 38 months, 99, 59
and 29% and from the time of first thermal ablation was 31
months, 89, 33 and 20%. Other groups have reported similar
survival results and the Milan group reported their results in 117
patients with up to four metastases, mean diameter 2.8cm. The
vast majority (103 out of 117 (88%)) of their patients had either
one or two tumors. The median survival in this cohort, who had
more limited disease than our cohort, was 36 months and their 3-
year survival was 46% (Solbiati et al, 2001). Vogl et al (2004) have
reported a similar median survival of 35 months in patients with
five tumours or less, maximum diameter 5cm. This group uses a
different thermal technique (neodymium yttrium aluminium
garnet (NdYAG) laser ablation) and a combination of CT guidance
for applicator placement and high field MR monitoring of the
thermal effect.
Analysis of patients with small solitary lesions, that is, surgical
disease but in those who were not suitable for surgery, reveals even
better survival figures. In our cohort, 34 patients had small solitary
tumours with a median diameter of 2.5cm, the mean and 3-year
survival from ablation was 67 months and 66%, respectively. Two
retrospective comparisons between surgery and RFA suggest
comparable survival between the two modalities (Elias et al,
2002; Oshowo et al, 2003); however, no prospective studies are
underway. A different approach is to use RFA as a ‘test of time’ –
this has been explored by the Milan group who have offered RFA
to surgical candidates (Livraghi et al, 2003a). Those who do not
develop further disease are spared a resection, those who develop
more extensive disease such that they are no longer operable on
short-term follow-up are spared an un-necessary and ineffective
surgical resection and those that recur can undergo resection. In
their cohort of 88 patients, 60% achieved complete ablation and
did not require resection. An on-going trial, sponsored by The
European Organisation for Research and Treatment of Cancer
(EORTC), is looking at a different patient population, those with
inoperable colorectal liver metastases. This trial aims to compare
the effect of ablation in conjunction with systemic chemotherapy
with systemic chemotherapy alone, that is, Chemotherapy þ Local
ablation vs Chemotherapy (CLOCC) trial. The acceptance criteria
are more generous than traditional acceptance criteria. Patients
can have as many as nine metastases with a maximum diameter of
4cm. We have retrospectively analysed our data according to the
CLOCC acceptance criteria. A theoretical projection comparing
our results with published Oxaliplatin and 5 fluorouracil (5FU)
data is shown in Figure 1 (Giacchetti et al, 2000). This projection
would suggest a useful survival advantage for the addition of
ablation to systemic chemotherapy but only the on-going
prospective study will provide the required evidence.
Complication rates of RFA are low with a mortality of o0.8%
and morbidity of 5–10%. Collateral damage can largely be avoided
by isolating the liver from adjacent vulnerable structures, for
example, colon or duodenum. This is usually readily achievable by
the instillation of o 1l of 5% dextrose through a 19G spinal needle
positioned between the ablation area and the vulnerable viscus.
Major bile ducts are susceptible to thermal injury and need to be
cooled. Bleeding is uncommon in patients with normal coagulation
and a normal liver parenchyma. Although one centre has reported
very high rates of tumour seeding following biopsy and RFA
(Llovet et al, 2001), in all other centres tumour seeding is
exceptional – 0.5% in one multicentre study which included 41
centres and over 2000 patients (Livraghi et al, 2003b). Secondary
infection of an ablation zone can occur, usually as a late
complication. Patients with bilio-enteric anastomoses or biliary
stents are particularly likely to develop secondary infection
presumably due to reflux of intestinal organisms into the biliary
tree and therefore these patients should receive 3 months of
rotating oral antibiotics post-ablation.
Breast
The median survival for patients with metastatic breast cancer is 2
years; however, those with hepatic metastases have a worse
prognosis. A small group of patients, 5–12%, have metastases
confined to the liver. Some centres offer hepatic resection in this
group and reported 3-year survival rates are 35–71%. The median
survival of patients with secondary liver metastases following
chemotherapy is 4.5 months; agents such as docetaxel may only
improve survival to 9–14.7 months. Liver metastases tend to be
resistant to hormonal manipulation, often being negative for
hormone receptors. Liver resection is being considered more
frequently but where resection is not possible RFA can be used for
patients with limited liver metastases who either have no extra-
hepatic disease or who have stable, controlled extra-hepatic
disease. We have follow-up on 19 patients treated with RFA, eight
had disease confined to the liver, with 11 having stable extra-
hepatic disease in addition. Seven patients with disease confined to
the liver at presentation are alive, as are six with extra-hepatic
disease, median follow up after RFA was 15 months (range 0–77).
Survival at 30 months was five out of 12 (41.6%), in addition seven
followed up for a median of 14 months (range 2–29) remain alive
and disease free. Livraghi et al treated 24 patients; 10 (41.6%) were
disease free at a median follow up of 10 months. Therefore, there
does appear to be a subgroup of patients who may benefit from
local ablative therapy.
Neuroendocrine
There are numerous treatment options for patients with neuro-
endocrine metastases, yet none is both widely applicable and
effective in reducing tumour load. For many of these patients, the
natural history of the disease whereby multiple often small
metastases develop over a period of years renders them
particularly suitable for a minimally invasive technique that can
be repeated frequently while sacrificing the least amount of normal
liver parenchyma. Radiofrequency ablation can be used to reduce
hormone secretion and/or to control total tumour load. In our
experience in 25 patients, we achieved local control of tumour
volume in 14 out of 19 (74%) patients. There was a complete
response in six, partial response in seven and stable disease in one
at a median follow-up of 21 months (range 4–75). Relief or a
reduction in hormone-related symptoms was achieved in nine of
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Figure 1 A theoretical projection of survival following RFA (in patients
with CLOCC acceptance criteria from our database) vs published
Oxaliplatin and 5FU chemotherapy results.
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diagnosis of liver metastases was 53 months (Gillams et al, 2005).
Symptomatic carcinoid patients require peri-procedural IV
Octreotide with careful monitoring during and after the procedure
as ablation, like other interventional procedures, can result in
hormone release and rapid changes in blood pressure.
PRIMARY HEPATOCELLULAR CARCINOMA
Percutaneous, image-guided ablation has been used in the
treatment of limited HCC for many years. Originally, chemical
methods were used with either acetic acid or 100% ethanol.
Ethanol is still used but increasingly thermal techniques such as
radiofrequency, interstitial laser coagulation and microwave are
becoming the preferred techniques. The presence of background
cirrhosis in the vast majority of patients with HCC reduces the
attractiveness of liver resection. Chemotherapy is ineffective and
only recently met-analyses have suggested that chemoembolisation
has an impact on survival (Camma et al, 2002). To be suitable for a
local ablative technique, patients should have one HCC nodule less
than 5cm or as many as three nodules o3cm in maximum
diameter. The underlying liver disease should be no more
advanced than Child Pugh class B. Retrospective comparisons of
percutaneous ethanol injection (PEI) and resection show similar
survival results (Livraghi et al, 1995). More recently, a prospective
comparison of radiofrequency and PEI in 102 patients showed a
significantly longer disease-free survival in the RFA group. The 1-
and 2-year local recurrence-free survival rates were 98 and 96% in
the RFA group compared to 83 and 62% in the ethanol injection
group (P¼0.002). There was a trend towards increased overall
survival with RFA but this has not yet reached significance
(Lencioni et al, 2003). Long-term survival post RFA has also been
reported in 206 patients with hepatic cirrhosis and early-stage
HCC. The overall survival was 97% at 1 year, 71% at 3 years and
48% at 5 years. Survival of Child-Pugh A patients (n¼144; 76% at
3 years and 51% at 5 years) was significantly better than that of
Child-Pugh B patients (n¼43; 46% at 3 years and 31% at 5 years,
P¼0.0006). A subgroup of 116 patients with Child-Pugh class A
cirrhosis and solitary HCC had 3- and 5-year survival rates of 89
and 61%, respectively (Lencioni et al, 2005). These results are
sufficiently compelling and it seems likely that RFA will become
the treatment of choice for early stage HCC.
PULMONARY NEOPLASIA
Radiofrequency ablation can be equally well applied to small lung
tumours, either primary or secondary. Several hundred treatments
have been performed worldwide, a sufficient number to develop a
reasonable safety profile (Steinke et al, 2004b). Overall, the
complication rate is very similar to that seen following percuta-
neous lung biopsy. Pneumothorax rates are of the order of 40%,
with only 10–15% requiring drainage or tube insertion. The need
for intervention depends on the patient population and underlying
lung disease, for example, in our cohort of 440 treatments in
patients with metastatic pulmonary lesions, it has not yet been
necessary to insert an intercostal drain. The pleural effusion rate is
similar at 10%. The ideal RFA candidate is a small, peripherally
located tumour. Again treatments can be performed under
conscious sedation as an overnight or day-case procedure. CT
guidance is required and CT fluoroscopy is useful. Successful
ablation is denoted by the development of ground glass shadowing
that completely encompasses the tumour. Initial consolidation
should be larger than the original tumour and then shrink over
time such that only a linear scar is visible at 12 months in 33% of
successfully treated tumours (Steinke et al, 2004a). Another useful
CT feature, which denotes successful ablation, is the absence of
enhancement within the consolidated area. Most centres will treat
patients with a limited number of metastases, for example, o3 per
lung. Again the very focal effects of ablation favour small tumours
o4 or 4.5cm. Centrally placed tumours carry the additional risk of
collateral damage and the increased likelihood that adjacent
cooling blood vessels may protect tumour cells and result in an
increased recurrence rate. Currently, RFA is offered to patients
with small tumours who are not suitable for conventional
treatment. Table 1 summarises the larger series in the literature.
Most have concentrated on technical success and complications
but Lee et al commented on survival. They reported on ablation of
32 tumours in 30 patients, 26 of whom had primary bronchogenic
carcinoma. Complete ablation was achieved in all six tumours less
than 3cm in diameter and mean survival for this subgroup was
19.7 months vs 8.7 months for the remainder. The use of RFA in
conjunction with radiotherapy and/or chemotherapy in the
treatment of primary lung cancer is being explored (Jain et al,
2003). New emphasis on screening high-risk populations for the
early detection of primary bronchogenic carcinoma will result in
the detection of earlier cancers. Not all of these patients will be
candidates for surgery, but may be candidates for RFA. As in the
liver, RFA is also useful for the treatment of recurrence or new
lesions in post surgical patients.
RENAL CELL CARCINOMA
Nephron sparing techniques such as partial nephrectomy have
been shown to be as effective as the traditional total nephrectomy,
while providing a reduced morbidity and better preservation of
renal function (Lee et al, 2000). Against this background, several
groups have explored local ablation techniques in early small renal
cell carcinoma and RFA has been very successful. Radiofrequency
ablation is usually performed under conscious sedation, with a
day-case or overnight stay, using US or CT guidance. Like HCC,
the well-defined encapsulated lesions are more amenable to
destruction by thermal techniques than ill-defined infiltrating
tumours such as hepatic metastases. Most experience has been
gained in patients who are not operable candidates or for whom
nephron sparing is particularly critical, that is, those who have had
previous contralateral nephrectomy, patients with multiple renal
cell carcinomas notably those with von Hippel Lindau syndrome.
Renal ablation is particularly successful for small, o4cm,
Table 1 Radiofrequency ablation in lung tumours
Authors
No. of tumours/
patients Histology 11/21
Tumour size
mean (range) or
maximum cm
Complete ablation –
no. of tumours
Length of
follow-up mean
(range) months
Akeboshi et al (2004) 54/31 13/41 2.7 (0.7–6) 32/54 (59%) 9.2 (5–18)
Gadaleta et al (2004) 69/34 6/28 o10 58/63 (92%) 9 (3–25)
King et al (2004) 45/20 0/20 (colorectal) o3.5 20/25 (80%) at 12 months 24 (5–31)
Lee et al (2004) 32/30 26/4 5.2 (1–12) 12/32 (38%) 12.5 (1–24)
Yasui et al (2004) 99/35 3/96 2.0 (0.3–8) 90/99 (91%) 7.1 (1–17)
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adjacent vessels resulting in incomplete ablation. In the largest
series published to date, the success rate, that is, complete ablation
on immediate contrast enhanced CT was 100% for exophytic
tumours and 45% for central tumours (Lui et al, 2003). The
complication rates are low and the collateral damage to intact
nephrons minimised such that renal function remains stable.
Table 2 summarises the main papers published to date.
SYMPTOMATIC PALLIATION
Occasionally, there is a role for RFA in symptom palliation.
Radiofrequency ablation has been successfully applied to bony
metastases to relieve pain. Charboneau and co-workers report
marked reductions in pain and analgesic requirements following
the treatment of limited, localised osteolytic bone metastases
(Goetz et al, 2004). One caveat is that there should be a specific,
clearly identifiable and localised area of bone destruction
responsible for the patients’ pain. Radiofrequency ablation has
also been used to debulk tumours to reduce pressure symptoms,
for example, dyspnoea or dysphagia.
CONCLUSION
Radiofrequency ablation has proven effective as a local technique
for tumour destruction. The complication profile is acceptable.
The challenge now is to define in which patient populations and
under what circumstances RFA should be used and how best to
combine this local technique with systemic therapy.
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